48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, K3
Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to Outside China
Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
Highlights Clinical Data to be Presented at the ESMO Congress 2026
Announces Licensing Agreement for KRAS-EGFR-Antibody Conjugate Cancer Therapy
HUTCHMED SANOVO Trial Shows Survival Benefit of ORPATHYS® Plus TAGRISSO®
Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Announcement Pursuant to AIM Rule 17 Schedule 2(g) Update
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis